Hepatitis C virus experimental model systems and antiviral drug research.
Hepatitis C virus experimental model systems and antiviral drug research.
复制标题
DOI：
10.1007/s12250-010-3134-0
复制
发表时间：
2010-08
影响因子：
5.5
通讯作者：
Uprichard, Susan L
中科院分区：
文献类型：
--
作者：
Uprichard, Susan L
据估计，全世界有1.3亿人慢性感染丙型肝炎病毒（HCV），使其成为全球肝病的主要原因。由于目前可用的聚乙二醇干扰素-α和利巴韦林治疗仅对一部分患者有效，因此开发新的HCV抗病毒药物是医疗保健的当务之急。本文综述了HCV抗病毒药物研究的实验模型，HCV抗病毒药物开发的最新进展，以及正在进行的积极研究，以促进新的HCV特异性治疗药物的开发。
An estimated 130 million people worldwide are chronically infected with hepatitis C virus (HCV) making it a leading cause of liver disease worldwide. Because the currently available therapy of pegylated interferon-alpha and ribavirin is only effective in a subset of patients, the development of new HCV antivirals is a healthcare imperative. This review discusses the experimental models available for HCV antiviral drug research, recent advances in HCV antiviral drug development, as well as active research being pursued to facilitate development of new HCV-specific therapeutics.